Arrakis Therapeutics
Signal active
Organization
Contact Information
Overview
Arrakis Therapeutics is a developer of a drug discovery platform intended to target RNA. The company's platform integrates leading-edge RNA bioinformatic and structural tools to produce a pipeline of rSMs to treat a range of disease including neurology, oncology and rare genetic diseases, enabling physicians to offer enhanced care.
About
Industries
Biotechnology, Pharmaceutical, Medical, Biopharma
Founded
2015
Employees
101-250
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Arrakis Therapeutics headquartered in United States, North America, operates in the Biotechnology, Pharmaceutical, Medical, Biopharma sector. The company focuses on Biotechnology and has secured $3.6B in funding across 32 round(s). With a team of 101-250 employees, Arrakis Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Arrakis Therapeutics, raised $38.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
2
Investors
6
Lead Investors
0
Total Funding Amount
$113.0M
Details
2
Arrakis Therapeutics has raised a total of $113.0M in funding over 2 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2019 | Early Stage Venture | 75.0M | ||
| 2017 | Early Stage Venture | 38.0M |
Investors
Arrakis Therapeutics is funded by 26 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Celgene | - | FUNDING ROUND - Celgene | 38.0M |
| OUP (Osage University Partners) | - | FUNDING ROUND - OUP (Osage University Partners) | 38.0M |
| Arrakis Therapeutics | - | FUNDING ROUND - Arrakis Therapeutics | 38.0M |
| Henri Termeer | - | FUNDING ROUND - Henri Termeer | 38.0M |
Recent Activity
There is no recent news or activity for this profile.